Manhattan Research Report Provides a Framework for Pharma to Navigate the Physician Social Media Landscape

Manhattan ResearchPharmaceutical and healthcare market research company Manhattan Research releases a new report providing in-depth data and analysis to help healthcare marketers, agencies, and publishers assess the physician social media landscape. The report found that the majority of U.S. physicians are using professional user-generated content in some form, primarily on blogs, open message boards, and other online media. In contrast, less than 20 percent of U.S. physicians have visited closed professional online communities despite high interest in these types of forums, representing a challenge for marketers seeking to leverage social media as an engagement tool. "Physician Social Media: Benchmarking Adoption and Assessing Strategic Opportunities" provides a framework for pharma companies to approach physician social media, discusses why traction of professional communities remains low, and explores challenges and opportunities for harnessing physician use of social media content.

"Framing the social media landscape is a critical first step in understanding the growing audience of physicians interacting with one another online," said James Avallone, Senior Digital Healthcare Analyst at Manhattan Research. "Since physicians' primary consumption of professional social media is happening outside the walls of existing closed physician-only communities, marketers need to evaluate other engagement opportunities, such as distributed content or niche communities."

"Physician Social Media: Benchmarking Adoption and Assessing Strategic Opportunities" draws from Manhattan Research's Taking the Pulse® v10.0 study conducted in Q1 2010 via online and offline survey methodology among 2,033 U.S. practicing physicians.

For more information about the report and its table of contents, please visit http://www.manhattanresearch.com/physician-social-media

About Manhattan Research Reports
Manhattan Research offers in-depth reports on important trends in physician and consumer use of digital media and technology for health. The report series draws from interviews conducted with nearly 20,000 physicians and consumers about their behaviors, attitudes, and future interests as it relates to their use of the Internet and other technologies for health and treatment decisions. Each PDF report includes a written analysis, supporting graphs and data, and strategic takeaways. For more information, please visit http://www.manhattanresearch.com/reports.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com.

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Japan becomes the first country to approve Roche's…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Rozlytrek® (entrectinib) for the treatment of a...

Breztri Aerosphere (PT010) approved in Japan for p…

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy...

FDA approves Amgen and Allergan's KANJINTITM (tras…

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTITM (trastuzumab-anns) for all approved ind...

Vitamin D may not help your heart

While previous research has suggested a link between low levels of vitamin D in the blood and an increased risk of cardiovascular disease, a new Michigan State University...

Human-on-a-chip model tests cancer drug efficacy a…

A reconfigurable "body-on-a-chip" model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organ...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

Researchers identify enzyme that suppresses immune…

Immunotherapies have transformed cancer care, but their successes have been limited for reasons that are both complex and perplexing. In breast cancer especially, only a ...